Peaches Biotech Receives €2M from the Government for Advanced Therapy Projects

Economic accolade for Peaches Biotech. The Spanish biotech company has raised €2 million from the Government to carry out advanced therapy projects, as confirmed by Peaches Biotech.

The latest aid that has been granted to Peaches Biotech is a loan of €598,084 from the Center for Industrial Technological Development (Cdti), an agency under the Ministry of Science and Innovation, financing from the Feder 2021-2027 funds.

Specifically, the company will use these resources to accelerate its research and development (R&D) for the project “Development of a tissue transfer solution to optimize cell nesting in advanced therapies”.

Cell therapies are characterized by the use of minimally manipulated cells with the aim of being able to treat diseases such as leukemia or lymphomas. Advanced therapies, on the other hand, use human genes, tissues, and cells that are manipulated in order to turn them into medicines.

If you want to find more details about Peaches Biotech and to read the latest business news of the day, download for free our companion app Born2Invest, available for free for both Android and iOS devices.

Peaches Biotech has also received help from the State Research Agency

This aid is added to those that the Madrid company has recently received. Specifically, the State Research Agency (AEI) of the Ministry of Science and Innovation has approved funding for a project related to cell therapies against pancreatic cancer and another on tumor labeling with immunotoxins.

The first of these two Peaches Biotech projects is the development of an investigative product for adoptive cell therapy opTcells for patients with gastrointestinal cancer. The initiative receives €636,818. 

The Spanish company leads a consortium in which companies from the group itself and public centers collaborate, such as the Health Research Institute of the Hospital 12 de Octubre. In this project, the objective is to generate autologous T cells from peripheral blood, to combat the patient’s own gastrointestinal tumor.

The second selected project is tumor labeling with granulysin-based immunotoxins and receives 945,669 euros. In this case, the participating companies of the Peaches Biotech group collaborate with the University of Zaragoza. The objective is to carry out a phase I clinical trial in cancer patients, selected by systemic injection of immunotoxins, which have already been successful in preclinical trials.

Peaches Biotech works in two areas of research, one with plasma and the other for the treatment of pancreatic cancer

Peaches Biotech is specialized in the creation of medicines based on advanced therapies, especially with cytokines, stem cells, or T-lymphocytes, which will allow patients to take advantage of new therapeutic options.

The company’s main areas of research work are Selective Rich Plasma (PRS), a patent-based process developed by Peaches Biotech that generates a suite of cytokines selective for various tissues. This procurement process results in a platform that has the potential to develop more than twenty different biologic drugs. The other area is opT cells, a process based on a license from Peaches Biotech for the treatment of pancreatic cancer.

__

(Featured image by Ibrahim Boran via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.